^
Association details:
| Biomarker: | MUC4 expression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) + INB03 (STAT3 inhibitor, TNF inhibitor, SIRPA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Blocking soluble TNF to Improve potency of trastuzumab deruxtecan by increasing internalization and antitumor innate immune response in a resistant HER2-positive breast cancer model
Published date:
12/02/2023
Excerpt:
T-DXd+DN increased the antitumor effect by 10%, 33% and 97% for T-DXd dose of 5, 2.5 and 1.25 mg/kg respectively. Combination of DN with T-DXd in MUC4 expressing HER2+ BC improves response to T-DXd alone by increasing T-DXd internalization and improving anti-tumor innate immune responses in the TME without increasing toxicity.
